Gallium [67Ga] citrate (Gallium [67Ga] citras)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Other diagnostic tools

Radioprophylactic and radiotherapeutic agents

Included in the formulation
  • Gallium citrate, 67Ga
    solution in / in 
    Federal Center for Design and Development of Nuclear Medicine Facilities of FMBA of Russia, FSUE     Russia
    • АТХ:

    V.09.H.X   Other radiopharmaceuticals for the diagnosis of inflammation and infections

    Pharmacodynamics:

    The compound of sodium citrate with a radionuclide G-67 in a sterile solution (pH 5-6) with a half-life of 78.26 hours, releases γ-quanta at the decay: 0.91 MeV (3%), 0.093 MeV (37%); 0.185 MeV (20.7%); 0.209 MeV (2.3%); 0.300 MeV (16.6%); 0.393 MeV (4.6%).

    It accumulates in primary and metastatic malignant neoplasms and in foci of nonspecific inflammatory processes.

    Pharmacokinetics:

    After intravenous administration, slowly withdrawn from the blood flow system. After 24 hours after administration, 10% of the drug remains in the blood.

    It accumulates in the liver tissue 3-5 hours to 10-12% and remains at this level for 48 hours.

    Half-life is 72 hours. Elimination of bile and kidneys in equal amounts (50% each).

    Indications:

    Used to diagnose systemic malignant diseases (Becker sarcoidosis, lymphogranulomatosis, etc.), metastatic and primary lung tumors, soft tissue sarcoma.

    ICD-10

    XX.Y40-Y59.Y57.6   Other diagnostic drugs

    XXI.Z00-Z13.Z03   Medical surveillance and evaluation in case of suspected disease or pathological condition

    Contraindications:

    Individual intolerance, pregnancy, the period of breastfeeding.

    Carefully:

    No data.

    Pregnancy and lactation:

    Recommendations for FDA - Category C. Contraindicated in pregnancy. Breastfeeding should refrain from breastfeeding for 24 hours after the study.

    Dosing and Administration:

    Intravenous at 1.5-2.0 MBq / kg 4 hours after eating.

    A positive result, indicating a pathological hyperfixation of the drug, is estimated by the coefficient of differential accumulation in excess of 1.3 relative to healthy tissues within a single organ.

    The highest daily dose: 2 MBq / kg.

    The highest single dose: 2 MBq / kg.

    Side effects:

    Nausea, fever, impaired sense of smell, transient leukocytosis.

    Allergic reactions.

    Overdose:

    Arterial hypotension, dyspnea.

    Treatment is symptomatic.

    Interaction:

    With simultaneous application with deferoxamine, possible distortion results of the study. It is recommended to stop the introduction of deferoxamine 48 hours before the scintigraphy.

    Special instructions:

    The use of the drug is possible only in a specialized hospital.

    Instructions
    Up